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by offering training opportunities, harmonized methods, tools, and 
data resources.
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Summary: In 1970, the World Health Organization (WHO) pub-
lished its well-known manifesto on clinical pharmacology, which for 
many years was the gold standard of the discipline.1 However, for 
the last 10 years or so it has been clearly in need of updating. This 
was finally achieved in 2012 after 3 to 4 years of work by the above-
named editors and a team of distinguished clinical pharmacologists 
from around the world. Their work was supported not only by the 
WHO but also by the Council for International Organizations of 
Medical Sciences (CIOMS) and the International Union of Basic and 
Clinical Pharmacology (IUPHAR). The document covers a number 
of different facets of the work of clinical pharmacologists but in par-
ticular highlights the role of clinical pharmacology in the delivery of 
health care.2 A recent questionnaire study in 31 European countries3 
has identified the weakness of clinical pharmacology in health care, 
particularly in its failure to provide clinical pharmacologic services 
that will promote the rational use of medicines (RUM).
The main chapter on “The Clinical Pharmacologist in Patient 
Care” covers a number of different ways in which the discipline 
can help deliver better patient care. The importance of the various 
modalities discussed will depend on the way in which health care is 
delivered in different countries. In a few countries, the clinical phar-
macologist (CP) will be directly involved in the care of both inpatients 
and outpatients. However, in the majority of countries, the CP will be 
more involved indirectly in patient care. In all countries, the CP will 
be closely involved in the critical evaluation of new and old therapies; 
in the work of Drug and Therapeutic committees, both national and 
local; and in services such as drug information, pharmacovigilance, 
and drug utilization studies. In addition, the CP in many countries is 
directly involved in therapeutic drug monitoring (TDM) and phar-
macogenetic services aiming to facilitate personalized medicine. The 
overall purpose of the manifesto is to strengthen the role of clinical 
pharmacology in achieving RUM, and this is the focus of the last 
chapter in the manifesto.
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Summary: The thalidomide disaster detected in 1961 initiated the 
first systematic international effort to address medicine safety issues 
at the global level. The Sixteenth World Health Assembly (1963) 
adopted a resolution (WHA 16.36) that reaffirmed the need for early 
action in regard to rapid dissemination of information on adverse 
reactions due to medicines and led to the WHO Programme for 
International Drug Monitoring. Under this program, systems have 
been developed in member states for the collection of individual 
case safety reports (ICSRs) and their evaluation. The reports are 
held in a central database, managed and maintained by the WHO 
Collaborating Centre for International Drug Monitoring, the Uppsala 
Monitoring Centre (UMC) in Sweden. The work of the UMC, with 
policy directives from WHO, serves the important function of con-
tributing to the work of national drug regulatory authorities and 
other relevant stakeholders, by improving the knowledge of safety 
profiles of medicines. As of June 2013, there are 144 countries partici-
pating in the program, with access to a WHO database containing > 8 
million ICSRs. This presentation will trace the growth of the program 
these last 40 years, address gaps in pharmacovigilance at national 
and international levels, determine trends and the most urgent PV 
priorities in defined settings, and identify the broad elements of a 
pharmacovigilance strategy that will promote quality health care 
and assure patient safety.
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Summary: Drug-induced liver injury (DILI) represents a significant 
cause of patient morbidity and mortality and is a major contributor 
to attrition in drug development. Prediction of clinical DILI remains 
difficult, particularly in cases characterized by marked interindividual 
variation. A lack of sensitivity, specificity, and an indirect mechanistic 
basis of currently used markers of hepatic injury remains a factor 
for the delayed identification of DILI. There is a need to discover, 
develop, and validate new biomarkers to better inform the medicinal 
chemist and the clinician. The ideal biomarker is 1 that is mechanism-
based, organ (cell) selective, and that can be used in both the clinic 
and laboratory models. Traditional biomarkers of DILI include leak-
age markers of cell death and markers of hepatic function. Preclinical 
DILI biomarker identification and validation have been focused on 
molecular biomarkers such as cytokeratin-18, high mobility group 
box-1 protein, and micoRNA-122, which are more informative with 
respect to chemical stress, adaptation, and mechanisms of cellular 
damage. Recent reports have shown that these hold translational 
application to inform both the sensitive identification of DILI and 
also its mechanistic basis in man. Furthermore, a number of these 
biomarkers provide enhanced prognostic information during clinical 
acetaminophen overdose. The integrated use of these and other mark-
ers will be discussed from a backdrop of imperfect current standards 
clinical Therapeutics
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in the context of understanding fundamental hepatology, transla-
tional applications, and the challenges associated with the clinical 
qualification of novel DILI biomarkers.
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Summary: Drug-induced liver injury (DILI) accounted for > 50% 
of cases of acute liver failure and 15% of patients undergoing liver 
transplantation between 1990 and 2002. One of the biggest fears is 
unpredictable idiosyncratic drug-induced liver injury (IDILI), which 
is a major contributor to the failure of a drug to process through 
development and is a major cause of withdrawal and black box warn-
ings. Due to the low concordance of the hepatotoxicity of drugs in 
animals and humans, a fundamental understanding of the mechanis-
tic basis from novel human-relevant in vitro models and biomarkers 
is critical for the development of effective strategies to prevent and 
predict DILI.
Hepatocellular activation of drugs has been widely implicated in 
immune-mediated DILI with concomitant activation of the adaptive 
immune system. Consistent with this hypothesis, a number of HLA 
alleles that are associated with DILI have been identified. Studies with 
patient PBMC and PBMC from drug-naive donors carrying HLA risk 
alleles have shown that drugs form specific associations with HLA 
risk alleles generating T-cell antigens and hence provide the immu-
nogenetic basis for the reaction. The identification of HLA alleles as 
predisposing factors for IDILI suggests that the adaptive immune sys-
tem also participates in reactions targeting the liver. Furthermore, the 
release of damage-associated molecular pattern molecules (DAMPs), 
such as high mobility group box-1, may serve to activate cells of 
the innate immune system. Certain mediators produced by innate 
immune cells may cause liver injury, but other factors are actually 
important to promote tissue repair and regeneration. However, to 
fully define cause and effect (bioactivation vs liver failure), an inte-
grated approach based on clinical studies, in vitro experiments, and 
animal models will be required, underpinned by appropriate bio-
analysis. We have been able to characterize covalent protein adducts 
in man formed by reactive drug metabolites (nevirapine, diclofenac) 
using techniques developed for β -lactam antibiotics that associate 
with various types of drug hypersensitivity. We have also developed 
in vitro models to look at the interplay between, genetic, chemical, 
and immunologic factors using cells from both hypersensitive and 
drug-naive individuals. Such techniques and concepts should enable 
us to elucidate various mechanistic pathways and thus define both 
chemical and biological variables that underpin this rare but serious 
form of DILI.
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Summary: There is a pressing need for faster and more efficient eval-
uation of new cancer agents to improve outcomes. Although many 
of the new targeted agents have proved disappointing, there is large 
range of new agents from varying classes that need to be evaluated 
alongside a need to evaluate biomarkers to identify more responsive 
patient subgroups effectively. The current evidence on biomarkers 
that predict the response to a therapy in oncology has often arisen 
from post hoc retrospective analyses of Phase III trial data. More 
recent trials are exploring novel ways to identify potential biomarkers 
of response much earlier in the drug development process, albeit in a 
more exploratory fashion. We suggest a new approach to trial design, 
which links novel treatment evaluation with the concurrent evalua-
tion of a biomarker within a confirmatory Phase II–III trial setting.
We describe such an approach used in a new protocol in advanced 
colorectal cancer called FOCUS4. The protocol will ultimately 
answer 3 research questions for a number of treatments and bio-
markers: (1) After a period of standard first-line chemotherapy, do 
targeted novel therapies provide strong signal of activity in differ-
ent biomarker-defined populations? (2) If so, do these definitively 
improve outcomes? (3) Is evidence of activity restricted only to the 
biomarker-defined groups?
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Summary: High development cost, low development success, cost-
disciplined health care policies, and intense competition demand an 
efficient drug development process. New compounds need to bring 
value to patients by being safe, efficacious, and cost-effective com-
pared with existing treatment options.
The goal of pharmacometrics/quantitative clinical pharmacology 
(also called Modeling and Simulation) is to optimize therapies for 
adult and pediatric patients through integration, innovation, and 
impact.1
-  Quantitatively integrate multisource data and clinical, biological, 
statistical, and mathematical concepts
-  Collaborate and innovate across disciplines, enhancing scientific 
understanding and knowledge
-  Impact and enhance key decisions in drug research and development
Pharmacometric approaches, including model-based meta-analy-
ses, allow for integration and utilization of biomarker, efficacy, and 
safety data and:
-  Provide a quantitative framework for comparative efficacy/safety 
assessments of drugs
-  Create opportunities to test assumptions through “virtual” experi-
ments and optimized clinical trials
-  Facilitate research and development of new therapies for adults 
and pediatrics
A sustained collaborative effort between academia, biotech/
pharma, hospitals and scientific societies involved in research, devel-
opment, and use of medicines is required to bring pharmacometrics/
quantitative clinical pharmacology to its full potential.
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Summary: Rationale: Chocolate is a popular food. Its consumption 
is largely associated with pleasure. Beliefs on its positive impact on 
health, physical, and mental strengths have been well established for 
